Fig. 7: IRF3 expression correlates with the activation of Wnt signaling and the survival of CRC, lung adenocarcinoma, and hepatocellular carcinoma patients.
From: IRF3 prevents colorectal tumorigenesis via inhibiting the nuclear translocation of β-catenin
a, b Correlation analysis for IRF3, LEF1, and TCF1 expression in CRC patients (n = 115) (a) or in human lung carcinomas (n = 67) (b). Fisher’s exact test. c, d Kaplan–Meier analysis for overall survival in a set of CRC patients (c) or human lung carcinomas (d) according to IRF3, LEF1, and TCF1 expression. e, f Combined expression status of IRF3, LEF1, and TCF1 in a set of CRC patients (e) or human lung carcinomas (f). Log-rank test, log rank, p < 0.0001. g Correlation between IRF3 expression and LEF1 or TCF1 expression in human hepatocellular carcinoma patients. n = 92 cases, Fisher’s exact test. h, i Kaplan–Meier analysis for the overall survival in a set of hepatocellular carcinoma patients according to IRF3, LEF, and TCF1 expression (h), or combined expression status of IRF3, LEF1, and TCF1 (i). *P < 0.05; **P < 0.01 by two-sided Pearson correlation coefficient (a, b, g). Log-rank test, log rank, P < 0.0001. *P < 0.05; **P < 0.01; ***P < 0.001 (c–f, h, i). See also Supplementary Fig. S7.
